Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 27, 2007. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to a share buyback.
- Shares Purchased: 3,500,000 Ordinary shares of 25 pence each.
- Purchase Date: March 27, 2007.
- Purchase Price: 1,381.0283 pence per share.
- Treasury Holdings Post-Purchase: 276,082,678 shares.
- Shares in Issue (Excluding Treasury): 5,734,236,296 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the acquisition of 3,500,000 shares for Treasury. Consequently, the total number of shares held in Treasury increased to 276,082,678. The number of shares in issue, representing total voting rights, stands at 5,734,236,296.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Points
- Verify the total number of shares in issue (5,734,236,296) for calculating ownership thresholds under Financial Services Authority Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (276,082,678) for accurate fully diluted share count calculations.
- Note that this filing does not contain operational or financial performance data for the period.